Recruiting OBSERVATIONAL NCT06726785
Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment (RLS-DRD2gene)
Gene Expression Changes on Extended Use of Dopamine Agonists in Restless Legs Syndrome (RLS)
Sponsor: HBC Immunology Inc
Conditions
Restless Leg Syndrome (RLS)
Updated 3 times since 2025 Last updated: Sep 9, 2025 Started: Jul 1, 2025 Primary completion: Dec 30, 2025 Completion: Feb 27, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06726785, this observational or N/A phase trial focuses on Restless Leg Syndrome (RLS) and remains actively recruiting participants. Sponsored by HBC Immunology Inc, it has been updated 3 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
3 versions recorded-
Oct 2025 — Present [monthly]
Recruiting
-
Apr 2025 — Oct 2025 [monthly]
Recruiting
-
Jan 2025 — Apr 2025 [monthly]
Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- HBC Immunology Inc
Data source: HBC Immunology Inc
For direct contact, visit the study record on ClinicalTrials.gov .